A peer-reviewed article just published in the Annals of Medicine titled “Multi-tiered screening and diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to pandemic” describes an algorithm for sustainable testing capacity to efficiently evaluate patients in response to a pandemic.
The multi-tiered, diagnostic strategy incorporates a rapid host immune response assay (such as FebriDx®) as a screening test, molecular confirmatory testing, and rapid IgM/IgG testing (such as COV-ID™) to assess benefit from quarantine/further testing and provide information on population exposure/herd immunity.
- Click here to access the study.
Lumos Diagnostics Partners with WHO and CDC for Antibiotic Awareness Week from November 18-24
From November 18-24, Lumos Diagnostics and partners of WHO’s World Antimicrobial Awareness Week and CDC’s Antibiotic Awareness Week will share what clinicians and patients need to know about antibiotics and the importance of using antibiotics wisely in both community and healthcare settings.